Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 15, 2025Open Access

Robust CRISPR Screens Identify TPL1 as a Novel Long Noncoding RNA Driving Triple-Negative Breast Cancer Hallmarks

View Full Paper
Ask AI
Bookmark
Share

Authors

RERamesh ElangoSRSunandini RamnarayananRVRadhakrishnan Vishnubalaji

Discussion

Loading...

Member takes

Overview

CRISPR screens reveal TPL1 regulates tumor growth in triple-negative breast cancer, indicating its therapeutic potential.

Key Points

  • Silencing tpl1 significantly impaired triple-negative breast cancer cell proliferation and invasive capacity.
  • CRISPR-Cas9 deletion screen of 1,029 lncRNAs identified tpl1 as crucial for modulating doxorubicin sensitivity.
  • Transcriptomic and proteomic analyses post-tpl1 knockdown showed impacts on key cancer pathways including ECM-receptor interaction.
  • TPL1 functions as a competing endogenous RNA, impacting various pro-tumorigenic targets, highlighting its role in TNBC.

Cite This Study

Elango et al. (2025) studied this question.

synapsesocial.com/papers/68c235ccb210217d6477224dhttps://doi.org/10.1101/2025.08.06.668327
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Linc01232 regulates mir-516a-5p/bcl9 axis to promote triple-negative breast cancer progression2025
  2. 2TRPML1 signaling at lysosomes-mitochondria nexus drives triple-negative breast cancer mitophagy, metabolic reprogramming and chemoresistance2025
  3. 3TSC1 as a therapeutic target in mTOR driven triple negative breast cancer 27702025
  4. 4The Emerging Role of LncRNAs in T-Cell Plasticity in Breast Cancer2025
  5. 5CRISPR-Cas9 Genome and Double-Knockout Screening to Identify Novel Therapeutic Targets for Chemoresistance in Triple-Negative Breast Cancer2025 · 1 citations